We read with interest the article entitled ''Efficacy and Safety of Triple Antiplatelet Therapy in Obese Patients Undergoing Stent Implantation'' by Gao et al. 1 This well-designed study investigated the effect of adjunctive cilostazol on dual antiplatelet therapy (clopidogrel þ aspirin) on cardiovascular events and stent thrombosis. They also assessed whether the benefit of triple antiplatelet therapy is derived from greater adenosine diphosphate-induced platelet inhibition in obese patients undergoing percutaneous coronary intervention (PCI). They demonstrated decreased target lesion revascularization and major adverse cardiac events in obese patients after drug-eluting stent (DES) implantation in the triple group. This may have been due to intensified platelet inhibition. Adding cilostazol to dual antiplatelet therapy was safe, reducing clopidogrel resistance without an increased risk of major complications such as serious adverse drug effects and bleeding.
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Dual antiplatelet therapy namely clopidogrel þ aspirin is a standard antiplatelet therapy for patients undergoing PCI to prevent stent restenosis. 2 On the other hand, cilostazol is a phosphodiesterase III inhibitor, which is used to treat claudication. 3 Cilostazol also decreases smooth muscle proliferation and intimal hyperplasia after endothelial injury, properties that resulted in trials evaluating its efficacy for the prevention of restenosis after PCI. In clinical trials, cilostazol reduced restenosis after angioplasty alone and PCI with bare-metal stents (BMSs). 4 For example, in the cilostazol for restenosis trial (CREST), patients undergoing successful BMS implantation were treated with aspirin and clopidogrel and then randomly assigned to cilostazol (100 mg twice daily) or placebo. 5 Seventy-five percent of the patients underwent coronary angiography at 6 months; cilostazol therapy was related to significant reductions in late lumen loss and angiographic restenosis. Efficacy was seen in patients at high risk of restenosis, such as those with small vessel or long lesions. The degree of late lumen loss, although less than with placebo, was greater than that seen with DESs. The efficacy of adding cilostazol to dual antiplatelet therapy was evaluated in the drug-eluting stenting followed by cilostazol treatment that reduces late restenosis in patients with long coronary lesions trial, which randomly assigned patients with lesions 25 mm in length to cilostazol or placebo in addition to dual antiplatelet therapy after implantation with a long zotarolimus-eluting stent. 6 Patients receiving triple compared to dual antiplatelet therapy had a significantly lower rate of the primary end point of in-stent late loss at 8-month angiography. On the other hand, possibly effective oral drugs (cilostazol, pioglitazone or rosiglitazone, and sirolimus), the reduction in late lumen loss may be significantly less than that achieved with a DES. In the Carotid Revascularization Endarterectomy versus Stenting trial, for example, the degree of late lumen loss, although significantly less than in the placebo arm, was greater than that seen in DES trials. It is possible that oral therapy in addition to a DES might be beneficial in high-risk lesions (eg, small vessels and long lesions).
Previous research suggested that obesity may be associated with increased on-treatment platelet reactivity. Gaglia et al sought to provide clarity to the hypothesis that increasing body mass index (BMI) could be associated with high on-treatment platelet reactivity. They evaluated the impact of triple antiplatelet therapy on platelet reactivity, reducing cardiovascular events, and the safety in obese patients undergoing coronary stenting. 7 They concluded that obese individuals had greater baseline platelet activity than nonobese patients, which suggests that while obese patients obtain a similar effect with low-dose aspirin, it may not have been sufficient to overcome their higher levels of platelet activation. 7 Contrary to previous reports, they found no association between BMI and ontreatment platelet reactivity as quantified by various platelet function tests. Based on that observation, one can suggest that modification of thienopyridine therapy in patients undergoing PCI solely based on BMI is an unfounded strategy. 7 Cardiovascular risk factors (eg, diabetes mellitus, hypercholesterolemia, hypertension, smoking, and overweight) may affect in-stent restenosis. 8 Mechanical rupture of coronary atherosclerotic plaque during stent implantation can increase serum levels of C-reactive protein (CRP). The stimuli responsible for the elevation of serum CRP level may arise from within atherosclerotic lesions, reflecting the degree of necrotic core or fibro fatty component after PCI. 9 The inflammatory degree of the de novo plaque in stent implantation may increase stent restenosis and may relate to lesion morphology. Because inflammation may play a role in stent restenosis, simple markers like CRP can be monitored cost-effectively and help identify high-risk patients. However, this concept requires proof in appropriately designed studies. 10 A large preprocedural plaque may limit stent expansion, necessitating adjunct high-pressure balloon inflation to optimize stent dimensions, which aggravates deep vessel wall injury; this includes plaque fracture, medial stretch, and dissection or rupture. On the other hand, the severity of vessel damage positively correlated with neointimal thickness after PCI. 11 Despite improvement in stent technology, such as DES, the problem of neointimal hyperplasia and restenosis remains. Deep wall structures can contribute to alterations in smooth muscle cell migration and degrees of smooth muscle cell proliferation in peristent area. Peristent neointimal proliferation may also be associated with preprocedural atherosclerotic plaque and may have different mechanisms of tissue proliferation. 12 Several studies have shown that postprocedural stent area or final minimal lumen dimensions predict in-stent restenosis by intravascular ultrasound (IVUS) analysis. Also, the use of IVUS in all patients and IVUS guidance during stent implantation might contribute to reduce the rate of myocardial infarction and stent thrombosis. 13 Periprocedural risk factors for restenosis such as site of stenting, oversizing, implantation of overlapping stents, and target vessel diameter along with change in vessel geometry are well known. 14 In conclusion, triple antiplatelet therapy was superior to dual antiplatelet therapy in decreasing thrombotic events in 12month cardiac events in obese patients undergoing PCI, mainly driven by a decrease in the incidence of clopidogrel resistance. 1 Nevertheless, risk factors for thrombotic events and in-stent restenosis in patients undergoing stent implantation are complex. Further large-scale prospective randomized clinical trials are needed.
